Skip Navigation


Annals of Oncology Advance Access originally published online on November 22, 2005
Annals of Oncology 2006 17(5):875; doi:10.1093/annonc/mdj074
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/5/875    most recent
mdj074v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bonneterre, M. E.
Right arrow Articles by Bonneterre, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonneterre, M. E.
Right arrow Articles by Bonneterre, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

letter to the editor

Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909–914)

The first 10% of the full text of this article appears below.

We were very much interested in Norum's paper [1Go] on the cost-effectiveness analysis of trastuzumab for metastatic breast cancer. The conclusion was that trastuzumab was not cost-effective in this setting. Some important points have to be discussed, which could modulate (on both sides) the results . . . [Full Text of this Article]

M. E. Bonneterre and J. Bonneterre*

Centre Oscar Lambret, 3 rue Frédéric Combemale, F-59000 Lille, France

* (E-mail: j-bonneterre@o-lambret.fr)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?